Annika Auranen - UTU Research Portal

Annika Auranen

- Docent,
Department of Clinical Medicine (Faculty of Medicine)

anaura@utu.fi

A cancer-specific detection of serum CA125 improves differential diagnosis of epithelial ovarian cancer from benign conditions. (2018)
- Clinical Cancer Research
Huhtinen K, Gidwani K, Kekki H, Hynninen J, Salminen L, Perheentupa A, Poutanen M, Auranen A, Grenman S, Lamminmaki U, Carpen O, Pettersson K
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer (2018)
- Oncology
Kemiläinen H., Huhtinen K., Auranen A., Carpén O., Strauss L., Poutanen M.
(18)F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer (2016)
- Gynecologic Oncology
Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J
A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources (2016)
- Clinical Chemistry
Gidwani Kamlesh, Huhtinen Kaisa, Kekki Henna, van Vliet Sandra, Hynninen Johanna, Koivuviita Niina, Perheentupa Antti, Poutanen Matti, Auranen Annika, Grenman Seija, Lamminmaki Urpo, Carpen Olli, van Kooyk Yvette, Pettersson Kim
Characterization of ascites and tumor-derived ovarian cancer stem-like cells (2016)
- Clinical Cancer Research
Kaipio K, Chen P, Huhtinen K, Mikkonen P, Ostling P, Mpindi JP, Lehtinen L, Roering P, Korpela T, Wennerberg K, Yadav B, Aittokallio T, Kulesskiy E, Hynninen J, Auranen A, Grenman S, Hautaniemi S, Carpen O
REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker (2016)
- PLoS ONE
Laura Lehtinen, Pia Vesterkvist, Pia Roering, Taina Korpela, Liisa Hattara, Katja Kaipio, John-Patrick Mpindi, Johanna Hynninen, Annika Auranen, Ben Davidson, Caj Haglund, Kristiina Iljin, Seija Grenman, Harri Siitari, Olli Carpen
Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy (2015)
- Cancer Research
Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomaki V, Lindell R, Hynninen J, Auranen A, Grenman S, Lehtonen R, Carpen O, Hautaniemi S
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma (2015)
- Gynecologic Oncology
Edqvist PHD, Huvila J, Forsstrom B, Talve L, Carpen O, Salvesen HB, Krakstad C, Grenman S, Johannesson H, Ljungqvist O, Uhlen M, Ponten F, Auranen A
High-grade serous ovarian cancer subtyping identifies pathways for targeted therapy (2014)
- European Journal of Cancer
Huhtinen K, Chen P, Mikkonen P, Kaipio K, Aittomaki V, Lindell R, Auranen A, Lehtonen R, Hautaniemi S, Carpen O
Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. (2014)
- Tumor Biology
Vallius Tuulia, Hynninen Johanna, Auranen Annika, Carpén Olli, Matomäki Jaakko, Oksa Sinikka, Virtanen Johanna, Grénman Seija
A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer (2013)
- Gynecologic Oncology
Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomaki J, Oksa S, Carpen O, Grenman S, Seppanen M, Auranen A
Characterization of primary high-grade serous ovarian cancer cell lines: Cell line and growth condition specific differences in stem cell marker expression and high-throughput drug screening (2013)
- Clinical Cancer Research
Roering P, Mikkonen P, Kaipio K, Huhtinen K, Hynninen J, Auranen A, Kulesskiy E, Yadav B, Aittokallio T, Grenman S, Wennerberg K, Carpen O
Identifying prognostically relevant subsets of endometrial cancer using unsupervised clustering of immunohistochemical staining data (2013)
- Virchows Archiv
Huvila J, Laajala D, Edqvist PH, Talve L, Grenman S, Ponten F, Aittokallio T, Carpen O, Auranen A
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? (2013)
- Gynecologic Oncology
Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A
Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. (2013)
- Gynecologic Oncology
Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A
FDG PET/CT in staging of advanced epithelial ovarian cancer: Frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread (2012)
- Gynecologic Oncology
Hynninen J, Auranen A, Carpén O, Dean K, Seppänen M, Kemppainen J, Lavonius M, Lisinen I, Virtanen J, Grénman S
A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families (2011)
- Acta Obstetricia et Gynecologica Scandinavica
Auranen Annika, Joutsiniemi Titta
Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer (2011)
- International Journal of Gynecological Cancer
Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S
Subspecialist training in surgical gynecologic oncology in the Nordic countries (2011)
- Acta Obstetricia et Gynecologica Scandinavica
Antonsen Sofie L, Åvall-Lundqvist Elisabeth, Salvesen Helga B, Auranen Annika, Salvarsdottir Anna, Hogdall Claus
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)
- British Journal of Cancer
Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A